---
title: "Orient Biotech: Net loss of 163 million yuan in the first half of 2025"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/254997756.md"
description: "Orient Biotech announced that in the first half of 2025, operating revenue was 403 million yuan, a year-on-year decrease of 3.62%. The net profit attributable to shareholders of the listed company was -163 million yuan, compared to -152 million yuan in the same period last year"
datetime: "2025-08-28T11:49:28.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/254997756.md)
  - [en](https://longbridge.com/en/news/254997756.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/254997756.md)
---

# Orient Biotech: Net loss of 163 million yuan in the first half of 2025

Orient Biotech announced that its operating revenue in the first half of 2025 was 403 million yuan, a year-on-year decrease of 3.62%. The net profit attributable to shareholders of the listed company was -163 million yuan, compared to -152 million yuan in the same period last year

### Related Stocks

- [688298.CN](https://longbridge.com/en/quote/688298.CN.md)

## Related News & Research

- [11:05 ETThe Church of Jesus Christ of Latter-day Saints Commits $25 Million to the UNICEF-led Child Nutrition Fund](https://longbridge.com/en/news/287088476.md)
- [Advance Metals Moves Towards Full Ownership of Myrtleford and Beaufort Gold Projects](https://longbridge.com/en/news/287147459.md)
- [14:47 ET6th Annual Midwest Design Awards Entry Period Now Open](https://longbridge.com/en/news/286808240.md)
- [China's Bio-Thera Gets US Nod for Golimumab Biosimilar](https://longbridge.com/en/news/286880573.md)
- [Compass Confirms High Grades and Wide Mineralized Intervals at the Massala Prospect | COGDF Stock News](https://longbridge.com/en/news/287206831.md)